Ehrlich ascites carcinoma cells (2 x lO6 cells/ mouse) were implanted into ICR female mice, weighing 20~25 g, on day 0 intraperitoneally.
Drugs were given intraperitoneally 10 times every day, starting on day 1. As seen in Fig. 1 , the combination therapy of PEP with leupeptin or E-64 exhibited significant increase of life span compared with PEP alone. PEP alone gave 150 T/C (%) and PEP plus leupeptin or E-64 gave 281 T/C (%) or 264 T/C (%), respectively.
Leupeptin or E-64 alone had no antitumor activity (Table 1) .
Aoyagi elalfi have previously reported that bestatin, an amino peptidase B inhibitor, increases the therapeutic activity of BLMagainst Ehrlich carcinoma inoculated to footpad. Sebti and Lazo5) and we have found that the activity of BLMhydrolase is inhibited by leupeptin and E-64. We examined the potentiation of the cytotoxicity of PEP by leupeptin and E-64 in vitro and in vivo. Leupeptin and E-64 potentiated the cytotoxicity of PEP in vivo as described here, but they failed to show an apparent potentiation in vitro against Chinese hamster ovary cells and L5178Y murine lymphoma cells (data not shown). The reason why they do not potentiate the cytotoxicity of PEP to these cells in vitro is unclear. However, it might be due to existence of some constituents in the culture medium which block activity of 
